Cannabielsoin acid A (CBEA-A)

Cannabielsoin Acid A (CBEA-A) is a compound obtained from the cannabis or marijuana plant. CBEA is a derivative of the Cannabigerovarinic Acid (CBGVA) which can be further broken down through the process of oxidization to give cannabielsoin (CBE). 

CBEA-A being one of the discoveries since 1940 when British chemist Robert S. Cahn reported the partial structure of cannabinol (CBN).

During research into the cannabis plant, CBEA-A was discovered alongside other compounds of CBD, CBC, CBG, CBN, and other compounds discovered during that research. The group of researchers isolated the compound from Hashish, a resin from an active flowering marijuana plant. 

The compound is formed through a series of transformations during the cannabis plant blooming stage. CBEA-A evolved from the precursor, cannabigerovarinic acid (CBGVA), which is also described by scientists as the mother of all cannabinoids.

Formed from CBGVA using manganese in the presence of air, it is synthesized by oxidative cyclization.

Related: What is CBN?

A molecule of CBEA-A contains multiple bonds, membered rings, hydroxyl groups, aromatic hydroxyl, non-H bonds, rotatable bonds, carboxylic acid, alcohol. Its structure involves atoms arrangement and bonds that keep atoms solidly fixed together. 

The interest in CBEA-A arose from the chemical composition and positioning of its power cells. CBEA-A and other compounds of such variations are still yet to be looked into, but much is expected on a futuristic look.

Researchers are looking to unlocking more functions of the cannabis plants asides its psychoactive or therapeutic ability, and hopes are on CBEA-A to being that key.

HOW DOES IT WORK?

Asides the chemical composition and structure of this compound, there is still no test as at this time to show or prove the functional characteristic and features of CBEA-A.

Related: CBD vs CBN

Since the carbons are present at the corners, researchers are hoping to explore what this means and how this will translate into functionality regarding its therapeutic benefits and if it will act in the same line as THC, CBD, CBN, and other well-identified cannabis compounds.

POSSIBLE THERAPEUTIC BENEFITS

Unlike THC, CBD, CBN, whose therapeutic function results have been ably solidified to a certain degree, researchers know nothing of what CBEA-A can do.

There are no tests or clinical trials to tell what its therapeutic possibilities or potentials can be. Medical practitioners, despite the little information we have on the cannabis plant and its compounds, have speculated a very much beneficial use of and for the plants to treating medical diseases and cases.

The conclusive logical corollary here is, CBEA-A is expected to have some benefits of its own.  

INTERESTING FACTS

• It contains a total of 59 molecule bonds.
• It is one of the few strains with multiple compounds in its chemical structure.
• ₂₂H₃₀O₅, it has a mass of 374.4706 g/mol.
• It may also be produced by photooxidation from CBDA.
• CBEA-A appears to be infrequently identified in natural sources

References

National Center for Biotechnology Information. “PubChem Compound Summary for CID 162113, Cannabielsoin” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Cannabielsoin. 

Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (February 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes”. Journal of Natural Products. 79 (2): 324–31. doi:10.1021/acs.jnatprod.5b0094